Investor Presentaiton
ORIENT-11 (1L nsqNSCLC): Sintilimab Combination Achieved
Significant Improvement in both PFS and OS
Progression-free survival
1
PFS (by IRRC)
Events
HR (95% CI)
P
Sint+chemo
42.1%
PL+chemo
65.6%
0.482
(0.362, 0.643)
<0.00001
0.75-
Sint+Chemo
PL+Chemo
0.5
Sintilimab in combination with chemo demonstrated larger decrease of
progression and death hazard as 1L therapy for non-squamous NSCLC
Product
Design
PFS (by IRRC)
ORIENT-11[1]
Sintilimab
Double-blind
KEYNOTE-189[2]
Pembrolizumab
Double-blind
NCT03663205[3] NCT03134872[4]
Tislelizumab
Open label
Camrelizumab
Open label
0.25-
Median (95% CI),
months
0
2
4
-10
6
8
10
12
14
16
Number at Risk
Months
HR (95% CI)
Sint+Chemo
266
231
202
143
63
25
3
3
0
P
0.48 (0.36, 0.64)
<0.00001
0.52 (0.43, 0.64)
<0.001
8.9 (7.1, 11.3) vs 5.0
(4.8, 6.2)
8.8 (7.6, 9.2) vs 4.9
(4.7, 5.5)
9.7 (7.7, 11.5) vs 7.6
(5.6, 8.0)
11.3 (9.5, NR) vs 8.3
(6.0, 9.7)
0.61 (0.46, 0.80)
0.0002
0.65 (0.46, 0.90)
0.0044
PL+Chemo
131
106
77
42
19
4
1
0
0
OS
Survival probaility
1
0.75
OS
Sint+Chemo
PL+Chemo
#
Median (95% CI),
months
HR (95%CI)
P
ESMO
congress
MHC-II antigen presentation pathway as a
predictive biomarker for sintilimab plus
chemotherapy as first-line treatment of
non-squamous NSCLC
Biomarker analysis of ORIENT-11 Study
Yunpeng Yang M.D.
Department of Medical Oncology, Sun Yat-sen University Cancer Center
State Key Laboratory of Oncology in South China
Collaborative Innovation Center for Cancer Medicine
Guangzhou, China
NR vs NR
0.61 (0.40, 0.93)
0.01921
20
NR vs 11.3 (8.7,
15.1)
Not reported
0.49 (0.38, 0.64)
<0.001
2020 Presidential
Symposium
AUGUST 8, 2020 | WORLDWIDE
ORIENT-11: sintilimab + pemetrexed + platinum as
first-line therapy for locally advanced or metastatic
non-squamous NSCLC
Li Zhang, Yunpeng Yang, Zhehai Wang, Jian Fang, Qitao Yu, Baohui Han, Shundong Cang, Gongyan Chen,
Xiaodong Me", Zhixiong Yang, Rui Ma, Minghong Bi, Xiubao Ren, Jianying Zhou, Baolan Li
State Key Laboratory of Oncology in South China. Collaborative innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, China Shandong
Cancer Hospital, China Peking University Cancer Hospital China: Tumor hospital of GuangZhuang Autonomous Region. China Shanghai Chest Hospital
China: Hanan provincial people's hospital, China Hartin Medical University Cancer Hospital, China Anhui Provincial Hospital, China. "Affiliated Hospital of
Guangdong Medical University Chine "Liaoning Cancer Hospital China The First Amiated Hospital of Bengbu Medical College China: Tian Cancer
Institute & Hospital China The First Amiated Hospital Zhejiang Universty China Beijing Chest Hospital Capital Medical University. China
Journal of
Oncology
NR (17.1, NR) vs 20.9
(14.2, NR)
0.72 (0.52, 1.01)
0.0272
ORIGINAL ARTICLE ARTICLES IN PRESS
Log in at IASLC Log in
Claim
Efficacy and safety of sintilimab plus pemetrexed and platinum as
first-line treatment for locally advanced or metastatic nonsquamous
non-small cell lung cancer: a randomized, double-blind, phase 3
study (ORIENT-11)
Yuripang Yang Zheha Wang Jan Fang Donglei Zhu Wen Zhang Li Zhang X + how at autho
4+ +#+|
0.5
Events
6-mo OS rate
HR (95% CI)
P
VIRTUAL
Sint+chemo
19.2%
89.6%
0.25
0.609
(0.400,0.926)
0.01921
PL+chemo
29.8%
80.4%
Number at Risk
T
T
T
0
2
4
6
8
10
12
14
16
Months
266
262
248
206
134
72
18
3
0
Sint+Chemo
PL+Chemo
131
128
113
92
Innovent
52
61
33
8
1
0
Confidential
Copyright©2021 Innovent Biologics
[1] Zhang L, et al. WCLC 2020
[2] Gandhi L, et al. NEJM 2018. DOI: 10.1056/NEJMoa1801005
[3] Lu S, et al. ESMO 2020
[4] Zhou CC, et al. WCLC 2019
20
20View entire presentation